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Background. Different healthy food patterns may
modify cardiometabolic risk. We investigated
the effects of an isocaloric healthy Nordic diet on
insulin sensitivity, lipid profile, blood pressure
and inflammatory markers in people with meta-
bolic syndrome.
Methods. We conducted a randomized dietary study
lasting for 18–24 weeks in individuals with fea-
tures of metabolic syndrome (mean age 55 years,
BMI 31.6 kg m2, 67% women). Altogether 309
individuals were screened, 200 started the inter-
vention after 4-week run-in period, and 96 (pro-
portion of dropouts 7.9%) and 70 individuals
(dropouts 27%) completed the study, in the
Healthy diet and Control diet groups, respectively.
Healthy diet included whole-grain products, ber-
ries, fruits and vegetables, rapeseed oil, three fish
meals per week and low-fat dairy products. An
average Nordic diet served as a Control diet.
Compliance was monitored by repeated 4-day food
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diaries and fatty acid composition of serum phos-
pholipids.
Results. Body weight remained stable, and no signif-
icant changes were observed in insulin sensitivity
or blood pressure. Significant changes between the
groups were found in non-HDL cholesterol (0.18,
mmol L1 95% CI 0.35; 0.01, P = 0.04), LDL to
HDL cholesterol (0.15, 0.28; 0.00, P = 0.046)
and apolipoprotein B to apolipoprotein A1 ratios
(0.04, 0.07; 0.00, P = 0.025) favouring the
Healthy diet. IL-1 Ra increased during the Control
diet (difference84,133;37 ng L1, P = 0.00053).
Intakes of saturated fats (E%, beta estimate 4.28,
0.02; 8.53, P = 0.049) and magnesium (mg, 0.23,
0.41; 0.05, P = 0.012) were associated with
IL-1 Ra.
Conclusions. Healthy Nordic diet improved lipid profile
and had a beneficial effect on low-grade inflammation.
Keywords: cardiovascular risk, inflammation, inter-
vention, metabolic syndrome, Nordic diet.
Introduction
Diet has a great impact on the risk and worldwide
burden of chronic diseases, including cardiovas-
cular diseases (CVD), the metabolic syndrome
(MetS) and type 2 diabetes [1, 2]. In particular,
the effects of dietary fatty acids on the metabolism
of serum lipids and lipoproteins and their connec-
tion to atherosclerotic process have been thor-
oughly investigated [3, 4], whereas their effects on
low HDL cholesterol [5–8], insulin resistance and
low-grade inflammation are still unclear [9, 10].
MetS, characterized by insulin resistance, central
obesity, clustering of cardiometabolic risk factors
and low-grade inflammation, is a major clinical
risk indicator of type 2 diabetes and CVD globally
[1, 2]. The Mediterranean diet, representing the
diet traditionally eaten in Southern Europe, has
long been related to improved health and preven-
tion of CVD, certain cancers and type 2 diabetes
[11–18]. Acceptance of the Mediterranean diet has
not been easy in other parts of the Western world,
probably due to difficulties in changing dietary
patterns, cultural differences in taste and limited
accessibility to various foods [19, 20]. A health-
enhancing regional Nordic diet has therefore been
proposed as an alternative to the Mediterranean
diet [21]. Recent studies suggest that a healthy
Nordic diet pattern is related to lower mortality [22]
and improved cardiovascular risk factors in short
term [23]. The aim of the present study was to
clarify whether a Nordic alternative for healthy food
pattern in a weight-stable condition would have
beneficial effects on insulin resistance, glucose
tolerance, serum lipids and lipoproteins, and
inflammatory markers in people with MetS. The
duration of our trial was decided to last for 18–
24 weeks to monitor adherence to the diet and
analyse the longer-term effects on glucose toler-
ance, insulin sensitivity and HDL-C metabolism,
because there is evidence that short-term results
may differ from that achieved in trials with longer
duration [24].
Materials and methods
Study design
The study was a randomized controlled multicentre
study performed in six centres [Kuopio and Oulu
(Finland), Lund and Uppsala (Sweden), Aarhus
(Denmark) and Reykjavik (Iceland)). The primary
outcome was insulin sensitivity and glucose toler-
ance, and secondary outcomes were blood lipids,
blood pressure and inflammatory markers as they
are all closely related to insulin resistance and are
risk factors for CVD. The study design and themain
measurements at each time-points are described in
Fig. 1.Therewas4-weekrun-inperiodduringwhich
all participants followed their habitual diet before
the participants, fulfilling the inclusion criteria,
were randomized into a control (Control diet) group
or a Healthy Nordic diet group (Healthy diet) for the
next 18–24 weeks. Randomization was performed
by matching according to gender and medians of
age, body mass index (BMI) and fasting plasma
glucose at screening, resulting in equal amounts of
certain strata classes amongst the groups. The
study participants were planned to visit the study
clinic at 2, 4, 8, 12, 16, 20 and 24 weeks. The major
visitswere in thebeginning (0 week) andat12andat
either 18 or 24 weeks (end of the study). The staff in
all study centres were trained to perform the mea-
surements in a similar way, and a common quality
management protocol was made familiar to all staff
members at each study site. The original protocol
was changed after a consultation with the NordF-
orsk Panel and Scientific Committee members after
the trial had been started for the following reasons:
(i) a shorterperiodof intervention (i.e. 18 weeks)was
considered to give the same information as that
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obtainedfrom24 weeks’ trial, (ii) totalcostswouldbe
reduced, and (iii) recruitment of study subjects was
easier for a shorter trial. Therefore, it was decided to
shorten the intervention to 18 (+/ 1) weeks in four
centres (Aarhus, Uppsala, Reykjavik and Oulu),
whereas in Lund and Kuopio where the intervention
was started earlier, the original study design was
followed. In Kuopio and Lund, the intervention was
carried out from October 2009 to June 2010, in
Aarhus, from January 2010 to September 2010, in
Oulu, from December 2009 to October 2010, in
Reykjavik, fromMarch 2010 to October 2010 and in
Uppsala, from June 2010 to November 2010. The
visits to the study centres were in line with the
original study plan, and the study was strictly
blinded regarding the measurements until the trial
was completed in all centres. Thus, in four centres
with a shorter intervention (18 weeks), the final
measurements according to the original study plan
were takenat18 weeks.Thestudyparticipantswere
advisedtokeepweightandphysicalactivityconstant
andnot to change their smokinganddrinkinghabits
or drug treatment during the study.
All study participants provided their written
informed consent, and local Ethical committees of
all the participating centres approved the study
protocol.
Screening of study participants and inclusion and
exclusion criteria
A screening examination was carried out 4 weeks
before the start of the dietary intervention. This visit
includedmedicalhistoryandaclinical examination,
including ECG (if deemed necessary by the study
physician),bodyweight,height,waistcircumference,
blood pressure, blood count, fasting plasma glucose
(screening value < 7 mmol L1) and fasting serum
creatinine, thyroid-stimulating hormone (TSH), liver
enzymes (gamma-glutamyltransferase, alanine ami-
notransferase, alkaline phosphatase), serum trigly-
cerides, total cholesterol and HDL cholesterol. The
inclusion criteria were age 30–65 years, BMI 27–
38 kg m2 and twoother of IDF’s criteria forMetS [2],
fasting plasma glucose 7.0 mmol L1 and a 2-h
glucose value < 11.1 mmol L1 at baseline detected
by an oral glucose tolerance test. As the applied IDF
criteria [2] concern the white population, only whites
were included in the study. Antihypertensive and
lipid-lowering medication was allowed but without
dosage changes during the trial. Themain exclusion
criteria included any chronic disease and condition,
which could hamper the adherence to the dietary
intervention protocol, poor compliance, chronic
liver, thyroid and kidney diseases, alcohol abuse
(>40 g per day), diabetes, fasting triglycerides
>3.0 mmol L1, total cholesterol >6.5 mmol L1 and
blood pressure >160/100 mmHg. A few study par-
ticipants with triglycerides between 3 and
<4 mmol L1 and with BMI between 38 and
<40 kg m2 were, however, included due to the fact
that they were very keen to take part in ongoing the
trial. Other exclusion criteria were a recent myocar-
dial infarction (<6 months), corticosteroid therapy,
psychiatric disorders needing drug treatment,
ongoing or recent treatment for cancer, coeliac
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Fig. 1 Study design in the Healthy Nordic diet intervention study. In four centres, the main outcome measurements were
taken at week 18. PBMCs = peripheral blood mononuclear cells.
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disease, allergies to cereals or fish and other serious
and extensive food allergies. Exceptional diets were
alsoanexclusioncriterionaswellasbingeeating [25].
Inhaled corticosteroids were permitted. Partici-
pants taking fish and vegetable oil supplements
or using stanol or sterol esters were asked to
discontinue using these supplements at least
4 weeks before the beginning of the intervention.
None of the study participants were excluded due
to noncompliance with regard to the study proto-
col. The allowed weight change during the study
was less than 4 kg.
Study participants
Participants were mainly recruited through adver-
tising in newspapers, but also from previous clin-
ical or epidemiological trials. Altogether 309
individuals were originally contacted and screened,
and they visited the study clinics as shown in the
flow chart (Fig. 2). After initial exclusions, 213 of
them were randomized, but there were 13 addi-
tional dropouts before the intervention. Thus, 200
individuals started the intervention, 104 in the
Healthy diet group and 96 in the Control diet
group. There were eight additional dropouts (five
women and three men) in the Healthy diet group
and 26 (20 women and 6 men) in the Control diet
group during the study, and altogether 96 individ-
uals in the Healthy diet group and 70 in the Control
diet group completed the trial. According to the
original study design, altogether 11 participants
(five in Healthy diet and six in Control diet groups,
respectively) were excluded from final analyses due
to weight change of over 4 kg. Reasons for dropouts
are given in the flow chart (Fig. 2), but we also
analysed the data without any exclusions.
Study diets and dietary counselling
The nutrient composition of the diets is summa-
rized in Table S1. Nordic nutrition recommenda-
tions formed the basis for the Healthy diet [26], and
the mean nutrient intake in the Nordic countries
formed the basis for the Control diet. The main
differences between the diets were the amount of
dietary fibre and salt, and the quality of dietary fat.
Both the Healthy diet and the Control diet were
isocaloric based on the evaluation of the habitual
diet (calculated from a 4-day food record) during
the run-in period. National nutrient databases
were used to calculate energy, macronutrient,
cholesterol, fibre and micronutrient contents [Aivo
Finland Ltd, Turku, based on the database of the
National Institute of Health and Welfare, Finland,
Dietist XP Software Package, version 3.1 (2009)
linked to Swedish Food Database 2009, Sweden,
Master Dietist System version 1.235 (2007) based
on Danish National Food administration database,
Denmark, and The Icelandic Food Composition
Database (ISGEM), Iceland].
In the Healthy Nordic diet, the main emphasis was
on food items such as whole-grain products,
abundant use of berries, fruit and vegetables,
rapeseed oil, three fish meals per week, low-fat
dairy products and avoidance of sugar-sweetened
products (Table 1). Key products were provided to
the study participants in both groups. The partic-
ipants in the Healthy Nordic diet group received
whole-grain products, for example, various breads,
berry products as frozen berries (e.g. strawberries,
black currants, bilberries) and dried powder as well
as dietary fats including rapeseed oil- and vegeta-
ble oil-based spreads. Local fruits (not provided)
were mostly apples, pears and plums. Further-
more, either fish was directly provided or the
expenses for consuming fish were covered to the
study participants. The individuals in the Control
diet group received low-fibre cereal products, for
example, breads with fibre content <6 g per 100 g,
and dairy fat-based spread, for example butter.
A clinical nutritionist or a dietician instructed the
diets at the 0-week visit. The study participants
kept dietary records regarding the intake of cereal
products, berry products, vegetables and fish.
309 Screened 
213 Randomized 
13 Dropouts
before the 
intervention 
104 Healthy diet 96 Control diet 
8 Dropouts 26 Dropouts 
control diet 12 
1, T2DM 1 
- Lack of motivation 2
- Too busy at work 2
- Unplanned visit abroad 1
- Pregnancy 1
- No reason given 2
- Unwillingness to follow the
- Personal reasons 3
- Lack of motivation 4
- Diagnosis of colon cancer
- Difficulties on blood draw 1
- Wish to lose weight 2
- No reason given 2
96 Healthy diet 70 Control diet 
Fig. 2 Flow chart and the number of participants and
dropouts from the study.
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These records were checked at each visit to the
study centre, including the visits when the grocer-
ies were delivered to the participants, that is, at 1–
2-week intervals. In addition to the 4-day food
record during the run-in period, the participants
kept 4-day food records also at weeks 2, 11 and 17
or 23 before the next visit to the study centre for
calculations of the dietary intake during the inter-
vention. All food records included four consecutive
days of which one was a weekend day.
Physical activity (total, leisure time, commut-
ing and at work) was monitored by a question-
naire. The aim was to keep physical activity
unchanged.
Biochemical and anthropometric measurements
Screening laboratory measurements, glucose and
lipid values and anthropometric measurements
were performed locally according to the standard
operational procedures agreed by all centres. Cen-
tralized analyses were as follows: apolipoproteins
A1 (Apo A1) and B (Apo B), cytokines and adipo-
kines (University of Eastern Finland and Kuopio
University Hospital), fatty acid composition of
serum phospholipids (Uppsala University), 24-h
urine sodium and potassium excretion (Copenha-
gen University) and plasma insulin (Aarhus Uni-
versity Hospital).
A standard 2-h oral glucose tolerance test (75 g D-
glucose) was performed after 12-h fast in the
morning. Blood samples were taken at the time-
points 0, 30 and 120 min to measure the concen-
trations of glucose and insulin.
Automated clinical chemistry analysers and rou-
tine clinical chemistry methods were used to mea-
sure glucose, cholesterol, triglycerides, HDL-C,
Apo A1 and Apo B, high-sensitive C-reactive
Table 1 Food items recommended in the study diets
Food group Healthy Nordic diet Control diet
Cereal products 25% of total energy as whole
grain of which 50% as rye,
barley and oat. Whole-grain pasta
and unpolished rice (6 g fibre per 100 g)
2–3 meals per week. Low salt content
(1.0%) in breads. Cereals with no added
sugar or honey. Bread (6 g fibre per 100 g)
6 slices per day
25% of energy as refined
of which 90% as wheat
Vegetables,
berries, fruit
(potatoes not included)
Fruits, vegetables and berries 500 g of which
berries 150–200 g per day, fruit 175 g per day
and vegetables 175 g per day
200–250 g, no bilberries
Dietary fats Rapeseed oil. Rapeseed and/or sunflower oil and/or soya
bean oil-based margarines with no trans fatty acids
and 2/3 of unsaturated fats (unsalted nuts and seeds
can be included in the diet)
Butter or other milk fat-based
spread (50% of total fat
as saturated)
Dairy products Low-fat liquid dairy 1% of fat
Cheese 17% of fat, 2 portions per day.
Sweetened yoghurts and other fruit milk products avoided.
No limitations
Fish 3 meals per week, 2 fatty fish (>4–5% of fat)
meals + 1 low-fat fish meal.
1 meal per week
Meat Preferably white meat, poultry. Low-fat choices. Game. No limitations
Beverages Avoidance of sugar-sweetened beverages.
Fruit and berry juices
<1 glass (1.5 dL) per day
No limitations
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protein (hs-CRP) and the liver enzyme activities.
For these automated analyses, the equipment and
system reagents were from Siemens Healthcare
Diagnostics (Tarrytown, NY, USA), Thermo Fisher
Scientific (Vantaa, Finland), Roche Diagnostics
GmbH (Mannheim, Germany) (in two laboratories),
Toshiba (Japan), Abbott Laboratories (Irving, TX,
USA), Ortho-Clinical Diagnostics and Johnson &
Johnson (New Brunswick, NJ, USA). The sample
material was either plasma or serum as required by
the analytical method in each laboratory. The
within-run variations (CV%) for the biochemical
measurements were 0.4–4.6%. The between-run
CV% was 0.5–6%. LDL-C concentrations were
calculated using Friedewald’s formula. Plasma
insulin was measured using the ELISA method
from Dako Denmark A/S, Glostrup, Denmark,
with a within-run and between-run CV% <8% and
<10%, respectively. Na+ and K+ were measured in
24-h urine samples on a Cobas Fara analyser
equipped with ion-selective electrodes (Roche). The
CV% for six intrabatch identical samples was <2%.
The 24-h excretion of each ion was calculated by
multiplying the concentration by the volume
excreted.
The plasma interleukins (IL) IL-1 beta, IL-1 Ra, IL-
6, IL-10 and tumour necrosis factor receptor II
(TNF RII) assays were performed using ELISA
methods from R&D Systems Inc, Minneapolis,
MN, USA. The within- and between-run variations
(CV%) were lower than 14%, except for IL-10 and
TNF RII, for which they were 1030%. Some high
values or individuals with greatly elevated (>2 SD)
inflammatory marker values were excluded from
statistical analyses (IL-1 Ra >1500 ng L1, three
values, IL-1 beta >4 ng L1, five values, two indi-
viduals, IL-6 >6 ng L1, eight values, one individ-
ual, IL-10 >5 ng L1, five values, two individuals,
TNF RII >3000 ng L1, five values, hs-CRP
>10 mg L1, eight values, one individual, and in
this case also, IL-6 values were excluded]. There-
fore, the exact numbers for each measurement
vary in the results given in the tables.
Serum high molecular weight (HMW) adiponectin
was measured using ELISA kit from Millipore (St
Charles, MO, USA) after the specific proteolytic
digestion of other multimeric adiponectin forms
(LMW, MMW adiponectin). The within-run CV%
was 2–6%, and the between-run CV was 12%.
Phospholipid fatty acid composition was analysed
as previously described in detail [27]. The CV
varied between 0.2% and 5% in successive gas
chromatography runs. The relative amount of fatty
acids is expressed as the percentage of the total
amount of identified fatty acids.
Indices for insulin sensitivity and secretion and
area under the curve (AUC) values for glucose and
insulin were calculated [28, 29].
Statistical analysis
Based on our experiences from previous clinical
trials [23, 29] and power calculations (alpha
<0.05, beta >0.8) on serum cholesterol, fasting
glucose and insulin, 80–90 subjects in each group
were expected to provide sufficient statistical
power. The primary analyses were performed
using linear mixed-effects models (nlme package
version 3.1–102) [30]. Models were fit using a
restricted maximum likelihood (REML) method
whilst ignoring missing observations. The age
variable was log10-transformed prior to analyses
to address the skewed distribution. The models
included the outcome of interest as dependent
variable, subject identifier as a random effect and
body weight, age, gender, study centre (i.e. also
study duration), study group, time-point and
study group * time-point interaction as covariates.
Analyses of systolic and diastolic blood pressures
included antihypertensive treatment as covariate,
and analyses of lipids and inflammation markers
included statin usage as a covariate. Subgroup
analyses of lipids and inflammation markers were
also performed excluding statin users. The aim of
the analyses was to study the effect of study group
on the outcome of interest during the intervention,
that is, the study group * time-point (baseline, 12
weeks and/or end of the intervention) interaction.
An additional analysis was performed to study the
association of IL-1 Ra with selected dietary vari-
ables within baseline, week 12 and weeks 18/24
measurements. The models included IL-1 Ra level
as dependent variable, subject identifier as a
random effect and body weight, age, gender, study
centre and statin usage as covariates. All analyses
were performed using R version 2.14 (R Develop-
ment Core Team, 2011) [31]. We also performed
statistical analyses without applying any exclu-
sion criterion, and the results remained quite
similar. Furthermore, between-group differences
in the main outcome measurements were tested
by t-test without any adjustment, and the results
were similar except for non-HDL cholesterol (see
the Results section).
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Results
Baseline characteristics
Table 2 shows the baseline characteristics by
group. The number of women was 63% in the
Control diet group and 70% in the Healthy diet
group. There were no significant differences
between these two groups in BMI, age, serum
lipids, Apo A1 or Apo B, glucose tolerance, blood
pressure, smoking, statin use or antihypertensive
drug treatment, or the prevalence of MetS (92% in
Control and 91% in the Healthy diet group).
Dietary data
At baseline, no major differences were found in
dietary variables between the groups (Table 3).
There were significant differences between the
groups during the intervention in the intakes of
carbohydrates, protein, total fat, saturated fatty
acids, polyunsaturated fatty acids, alpha-linolenic
acid, fibre, dietary cholesterol, salt and sodium,
beta-carotene, vitamin C, vitamin E, potassium and
magnesium, generally favouring the adherence to
the Healthy Nordic diet. As for the major food items
(total fat, saturated fats, monounsaturated and
polyunsaturated fatty acids and dietary fibre), the
goals of the Healthy diet were satisfactorily
achieved (Supplemental Table S1). There was no
significant difference between the groups in the
reported alcohol intake at baseline, and the
changes in alcohol intakes were quite modest
during the trial (Table 3). No significant differ-
ences were found in the mean values (before and
during the intervention) or changes in 24-h
sodium and potassium excretion between the
groups in the subgroups of individuals with
reliable urine collection (N = 84 for Healthy diet
group and N = 62 for Control diet group). The
figures [mean (SD)] for 24-h urinary sodium and
potassium excretions (mmol per day) before and
during the trial (12-week and 18- to 24-week
collections combined) were as follows: 143.5
(51.5) and 141.5 (64.9) for sodium and 66.7
(65.3) and 65.3 (22.5) for potassium in the
Healthy diet group and 150.7 (72.4) and 148.2
(60.0) for sodium and 69.4 (24.8) and 71.1 (24.7)
for potassium in the Control diet group, respec-
tively, and the changes in sodium and potassium
excretions between the groups (1.8 mmol per day
Table 2 Baseline characteristicsa
Healthy diet (n = 99) Control diet (n = 90)
Sex (female) 69 (70%) 57 (63%)
Age (years) 54.0 (8.5) 54.9 (8.6)
BMI (kg m2) 31.6 (3.5) 31.7 (2.8)
Total cholesterol (mmol L1) 5.30 (0.88) 5.24 (0.98)
LDL cholesterol (mmol L1) 3.25 (0.80) 3.21 (0.89)
HDL cholesterol (mmol L1) 1.36 (0.33) 1.33 (0.41)
Triglycerides (mmol L1) 1.52 (0.75) 1.61 (0.80)
Apo B (g L1) 1.06 (0.26) 1.05 (0.26)
Apo A–I (g L1) 1.44 (0.20) 1.40 (0.24)
0 h Glucose (mmol L1) 5.8 (0.6) 5.7 (0.6)
2 h Glucose (mmol L1) 6.2 (1.6) 6.8 (2.1)
Systolic BP (mmHg) 130 (15) 130 (16)
Diastolic BP (mmHg) 82 (10) 82 (11)
Statin use 18 (18%) 26 (29%)
Smoking 4 (4%) 9 (10%)
Drug treatment for hypertension 56 (57%) 42 (47%)
Metabolic syndrome 91 (92%) 78 (87%)
Values are given as means (SD) or numbers (N, %).
aParticipants with body weight change over 4 kg were excluded due to the study design (five in the Healthy diet and six in
the Control diet groups, respectively).
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(16.7; 20.2, P = 0.85) and 2.5 (9.1; 4.1,
P = 0.46) were negligible.
Total physical activity and leisure time physical
activity remained unchanged during the study
(data not shown).
Fatty acid composition of phospholipids
Table S2 shows the results of the fatty acid com-
position. The main differences reflect the different
intakes of milk fat between the groups, for exam-
ple, myristic acid (P = 0.08) and especially penta-
decanoic acid proportions (P = 0.00024) decreased
in the Healthy diet group compared with the
Control diet group. In addition, the changes in
oleic (P = 0.039) acid and alpha-linolenic acids
(P = 0.076) were different between the groups, the
latter reflecting the higher intake of rapeseed oil in
the Healthy diet group. Changes in dihomo-
gamma-linolenic acid proportions were markedly
different (P = 0.00021) with a decrease in the
Healthy diet group and an increase in the Control
diet group. Proportions of eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) increased
in the Healthy diet group and decreased in the
Control diet group (between-group difference;
P < 0.0001 for both fatty acids).
Body weight, glucose tolerance and liver enzymes
There were no significant within-group changes in
body weight, and importantly, the groups did not
differ with regard to the mean change in body
weight during the trial. There were no differences in
any of the variables reflecting glucose metabolism
or blood pressure at the end of the trial, similarly
serum liver enzyme activities did not change
significantly during the intervention (Table 4).
Table 3 Dietary data at baseline and during the study (2-, 12- and 18/24-week data (mean and SD) by group, and the
differences in dietary variables at the end of the study with 95% CI
Healthy
diet
(0 week)
Healthy
diet (2, 12,
18/24 week)
Control
diet
(0 week)
Control diet
(2, 12,
18/24 week)
Estimate
(95% CI)
Significance
(P-value)
Energy (kJ) 8523 (1976) 8545 (1812) 8429 (2050) 8540 (1886) 77 (496 to 342) 0.72
Carbohydrate
(E%)
45.7 (6.0) 46.8 (6.4) 46.1 (6.7) 44.6 (6.5) 2.66 (0.94 to 4.37) 0.0024
Sucrose (g) 39.6 (23.6) 34.7 (18.4) 38.7 (17.6) 35.7 (19.8) 2.16 (7.19 to 2.86) 0.4
Protein (E%) 16.6 (2.8) 17.5 (3.2) 16.9 (2.3) 16.2 (2.3) 1.51 (0.69 to 2.33) 0.00033
Fat (E%) 33.2 (6.3) 31.7 (5.3) 32.9 (5.9) 35.2 (5.2) 3.63 (5.28 to 1.98) 1.90E-05
SFA (E%) 12.6 (3.3) 10.1 (2.5) 13.1 (3.1) 14.8 (2.9) 4.3 (5.1 to 3.4) 3.70E-21
MUFA (E%) 11.3 (2.7) 11.6 (2.5) 11.1 (2.3) 12.1 (2.2) 0.7 (1.3 to 0.0) 0.058
PUFA (E%) 4.9 (1.7) 6.8 (2.0) 4.6 (1.4) 4.4 (1.2) 2.1 (1.6 to 2.6) 3.30E-16
Linoleic acid (g) 8.2 (3.6) 8.8 (4.7) 7.2 (2.4) 8.0 (3.0) 0.1 (1.3 to 1.1) 0.89
Alpha-linoleic acid (g) 1.5 (1.6) 2.0 (1.8) 1.2 (0.7) 1.3 (0.6) 0.5 (0.2 to 0.8) 0.0017
Fibre (g) 22.4 (7.1) 34.7 (10.2) 20.3 (6.1) 15.9 (4.5) 16.8 (14.8 to 18.9) 2.50E-45
Cholesterol (mg) 284 (125) 248 (116) 285 (114) 297 (116) 45 (79 to 11) 0.01
Salt (g) 7.4 (2.2) 6.5 (2.2) 7.2 (2.5) 7.1 (2.3) 0.80 (1.40 to 0.20) 0.0094
Beta-carotene (lg) 3254 (3067) 4229 (4126) 2775 (3151) 1922.4 (1682) 1882 (987 to 2778) 4.30E-05
Vitamin C (mg) 117 (64) 164 (73) 106 (81) 79 (57) 75 (56 to 94) 7.00E-14
Vitamin E (mg) 9.2 (3.5) 12.1 (4.0) 8.3 (3.0) 7.8 (2.8) 3.5 (2.5 to 4.4) 1.40E-11
Folate (lg) 322 (260) 351 (146) 253 (76) 251 (98) 33 (13 to 79) 0.16
Sodium (mg) 2945 (881) 2609 (889) 2848 (977) 2817 (863) 293 (523 to 63) 0.013
Potassium (mg) 3468 (933) 3793 (972) 3419 (1083) 2938 (886) 796 (593 to 1000) 9.60E-14
Magnesium (mg) 351 (97) 398 (101) 336 (100) 290 (82) 93 (72 to 113) 1.60E-17
Alcohol (E%) 3.0 (4.1) 2.3 (3.5) 2.8 (3.9) 3.3 (4.2) 1.21 (2.09 to 0.32) 0.0075
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Serum lipids and apolipoproteins
There were significant decreases in non-HDL-C
(adjusted P = 0.04, t-test P = 0.20) and nonsignificant
trends towards differences between the groups in
changes of LDL-C (P = 0.06), Apo B (P = 0.08) and
HDL-C (P = 0.074). Furthermore, LDL-C to HDL-C
and Apo B to Apo A1 ratios decreased in the
Healthy diet group compared with the Control diet
group. When statin users were excluded, the
changes in lipid and lipoprotein values were
numerically quite similar to that seen in the entire
study population (data not shown). Figure 3
depicts the changes in LDL-C, HDL-C and Apo B
and Apo A1 with time separately for those with 18-
and 24-week follow-up. It is clear that the duration
Table 4 Clinical and biochemical values at baseline and at the end of the study (mean and SD) by group, and the differences
in changes with 95% CI
Healthy diet (N = 88–99) Control diet (N = 64–90)
Estimate
(95% CI) P-value
Baseline
mean (SD)
End
mean (SD)
Baseline
mean (SD)
End
mean (SD)
Body weight, kg 90.1 (13.3) 90.4 (13.9) 91.9 (12.6) 92.9 (13.1) 0.5 (1.0 to 0.1) 0.097
Total cholesterol,
mmol L1
5.30 (0.88) 5.16 (0.92) 5.24 (0.98) 5.17 (0.97) 0.12 (0.30 to 0.07) 0.21
LDL cholesterol,
mmol L1
3.25 (0.80) 3.12 (0.79) 3.21 (0.89) 3.20 (0.88) 0.15 (0.31 to 0.01) 0.058
HDL cholesterol,
mmol L1
1.36 (0.33) 1.41 (0.37) 1.33 (0.41) 1.32 (0.37) 0.05 (0.01 to 0.11) 0.074
Non-HDL
cholesterol, mmol L1
3.93 (0.91) 3.71 (1.00) 3.86 (1.05) 3.80 (1.06) 0.18 (0.35 to 0.01) 0.04
Triglyceride, mmol L1 1.52 (0.75) 1.41 (0.66) 1.61 (0.80) 1.46 (0.49) 0.03 (0.18 to 0.11) 0.64
Apo B, g L1 1.06 (0.26) 1.04 (0.27) 1.05 (0.26) 1.06 (0.25) 0.04 (0.08 to 0.00) 0.081
Apo A1, g L1 1.44 (0.20) 1.47 (0.26) 1.40 (0.24) 1.40 (0.23) 0.03 (0.01 to 0.08) 0.19
LDL-C/HDL-C ratio 2.53 (0.89) 2.38 (0.89) 2.63 (1.10) 2.61 (0.98) 0.15 (0.29 to 0.00) 0.046
Apo B/Apo A1 ratio 0.76 (0.22) 0.73 (0.22) 0.77 (0.23) 0.78 (0.22) 0.04 (0.07 to 0.00) 0.025
IL-1 Ra, ng L1 366 (217) 364 (194) 345 (163) 441 (262) 84 (130 to 37) 0.00053
IL-1 beta, ng L1 0.20 (0.27) 0.23 (0.44) 0.26 (0.37) 0.25 (0.36) 0.05 (0.07 to 0.18) 0.42
IL-6, ng L1 1.53 (0.71) 1.69 (1.06) 1.51 (0.82) 1.59 (0.92) 0.12 (0.18 to 0.42) 0.44
IL-10, ng L1 1.16 (0.68) 1.20 (0.75) 1.16 (0.57) 1.23 (0.72) 0.01 (0.22 to 0.21) 0.96
sTNFRII, ng L1 1936 (437) 1911 (421) 1911 (407) 1923 (381) 39 (138 to 62) 0.45
hsCRP, mg L1 2.6 (2.3) 2.7 (2.2) 2.4 (2.0) 2.3 (1.9) 0.3 (0.2 to 0.8) 0.18
HMW adiponectin, lg L1 5.43 (3.48) 5.63 (3.27) 4.72 (3.32) 4.68 (3.12) 0.05 (0.37 to 0.47) 0.81
0 h Glucose, mmol L1 5.75 (0.60) 5.67 (0.65) 5.70 (0.62) 5.58 (0.74) 0.02 (0.15 to 0.12) 0.79
2 h Glucose, mmol L1 6.15 (1.57) 6.47 (1.97) 6.78 (2.14) 6.69 (2.11) 0.36 (0.08 to 0.79) 0.11
InsAUC0-30/
GluAUC0-30
25.59 (13.70) 25.62 (11.57) 29.16 (18.12) 30.56 (17.33) 1.13 (4.10 to 1.85) 0.46
Matsuda
Insulin
Sensitivity Index
6.23 (3.34) 6.27 (3.92) 5.65 (3.61) 6.31 (4.76) 0.25 (1.13 to 0.63) 0.58
Systolic BP, mmHg 129.9 (14.6) 126.2 (14.6) 129.8 (16.0) 127.9 (15.0) 2.0 (5.7 to 1.66) 0.28
Diastolic BP, mmHg 82.5 (10.3) 79.7 (10.5) 81.8 (10.9) 79.2 (10.0) 1.2 (3.4 to 1.0) 0.29
Gamma-
glutamyltransferase, U/L
37.17 (28.76) 38.63 (31.47) 34.75 (21.71) 37.58 (28.07) 1.63 (6.57 to 3.32) 0.52
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of the study affects the trends and suggests some
heterogeneity in changes across the centres.
Inflammatory markers
The IL-1 Ra level increased in the entire Control
diet group (84; 130 to 37 ng L1; group differ-
ence comparing the Healthy diet to Control and
95% CI, P = 0.00053) and in those individuals not
using statins (79; 130 to 27, ng L1,
P = 0.003)]. Figure 3 shows that the longer the
duration of intervention was, the larger was the
group difference in IL-1 Ra. In the fully adjusted
analysis (age, gender, body weight, statins, study
centre) including three time-points (0, 12 and
18/24 weeks), the intakes of saturated fats [E%,
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4.28 (95% CI 0.02; 8.53), P = 0.049] and magne-
sium [mg, 0.23 (0.41; 0.05), P = 0.012] were
significantly associated with IL-1 Ra levels
(Table 5). Otherwise, no differences were observed
in inflammatory markers or HMW adiponectin
concentrations between the groups. However, the
concentrations of IL-1 beta and IL-10 were low or
below functional sensitivity in the majority of the
participants (70% and 40% of samples, for IL-1
beta and IL- 10, respectively).
Discussion
In this randomized trial carried out with isocaloric
diets, the Healthy Nordic diet, based on Nordic
dietary recommendations, did not modify insulin
sensitivity and glucose tolerance but resulted in
significant between-group changes in non-HDL-C,
LDL-C to HDL-C ratio and Apo B to Apo A1 ratio
favouring protection from atherosclerosis. Inter-
estingly, as compared to the Healthy diet group,
there was a significant increase in IL-1 Ra level
with time in the Control diet group. It should be
emphasized that our aim was isocaloric study
design because we wanted to examine the effect
of quality of diet on glucose metabolism, risk
factors and inflammation. Concomitant weight loss
would make it difficult to interpret the results in
this kind of dietary intervention regarding the
quality of an experimental diet [13]. It can be
argued that the results are simply in line to that
what can be expected from dietary changes made.
However, besides macronutrient and dietary fibre
intakes also micronutrients and non-nutrients
may have health effects [12], as was the case in
the present study, for example, regarding the link
between magnesium intake and the change in IL-1
Ra. Thus, obviously, the present study provides
novel data on the health effects of Nordic dietary
pattern and adds to our current knowledge on the
impact of this diet on multitude of metabolic
disorders in individuals with features of MetS,
not examined previously in detail.
As judged from the dietary records, compliance to
the Healthy diet was satisfactory. With regard to
phospholipid fatty acid composition, the decrease
in dihomo-gamma-linolenic acid proportions and
increase in EPA and DHA proportions in the
Healthy diet group can be ascribed to higher fish
intake [32]. Instead, there were no significant
differences between the groups for oleic acid
content. It is known from controlled feeding
trials, where saturated fat (mainly from high-fat
dairy products) have been replaced by rapeseed
oil in the diet, that the phospholipid proportions
of oleic acid, linoleic acid and alpha-linolenic acid
increase significantly, whereas the proportions of
palmitic acid, palmitoleic acid, dihomo-gamma-
linolenic acid and pentadecanoic acid decrease
[33].
The lack of effects on glucose metabolism may
partly reflect the isocaloric dietary design and that
it may be difficult to improve glucose metabolism in
established MetS without any concomitant weight
loss or more marked changes in diet [23, 29].
The reduction in Apo B to Apo A ratio and non-
HDL-C concentration during the healthy Nordic
diet indicates the reduction in those lipid fractions
that are known to promote atherosclerosis [5, 6].
Whilst the non-HDL-C and Apo B lowering effect of
the healthy Nordic diet was expected, the trends
towards an elevated HDL-C and Apo A1 were less
expected, because lowered HDL-C was reported,
for example, in the DASH study [34] and after 6-
week intervention in the NORDIET study [23],
possibly explained by the lower fat content in those
diets. However, a diet rich in berries [35, 36],
vegetables, fruit and whole grains and foods with
low glycaemic index may result in an elevation of
HDL-C in the longer term [24, 37]. Indeed, Esposito
et al. also reported an elevation in HDL-C by
0.1 mmol L1 in their study on the long-term
effects of a Mediterranean-type diet [14], but there
was simultaneous weight reduction during that
study [14]. According to the present study design,
body weight, physical activity and alcohol intake
Table 5 Association of IL-1 Ra with selected dietary
variablesa
Estimate (95% CI) P-value
Magnesium (mg) 0.23 (0.41 to 0.05) 0.012
SFA (E%) 4.28 (0.02 to 8.53) 0.049
Potassium (mg) 0.02 (0.04 to 0.00) 0.073
Fat (E%) 2.04 (0.49 to 4.57) 0.11
MUFA (E%) 5.13 (1.14 to 11.40) 0.11
Vitamin C (mg) 0.16 (0.35 to 0.04) 0.12
Fibre (g) 0.95 (2.39 to 0.50) 0.2
PUFA (E%) 1.79 (9.06 to 5.47) 0.63
Data are given as beta estimate with 95% CI.
aAfter adjustment for age, gender, body weight, statin use
and centre (study duration).
M. Uusitupa et al. Healthy Nordic diet and CVD risk
62 ª 2013 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine, 2013, 274; 52–66
remained essentially unchanged during the trial.
Thus, these confounders could not explain the
observed results of HDL-C in our study. It is
noteworthy that not all studies on the Mediterra-
nean-type diet have reported beneficial effects [38].
The changes in systolic and diastolic blood pres-
sure were not significantly different between the
groups. This is in contrast to that seen in the DASH
[39] or NORDIET studies [23] with quite similar
dietary pattern. In the present study, fat intake was
higher as compared to the DASH and NORDIET
studies. Furthermore, we achieved only modest
changes in self-reported salt intake, and based on
24-h urinary sodium excretion, no reduction in the
sodium intake was found in both groups. Perhaps
more effort might have been needed in dietary
counselling and use of low-salt products.
Amongst the cytokines, IL-1 Ra was markedly and
consistently elevated during the Control diet
because there was a worsening in the quality of
diet. IL-1 Ra is considered as one of the most
sensitive markers of inflammation in obesity and
MetS [40–44]. Furthermore, elevated levels of IL-1
Ra have been shown to predict the onset of type 2
diabetes and progression of MetS to overt type 2
diabetes after adjustment for obesity and hs-CRP
[43]. The observed elevation of IL-1 Ra may be a
compensatory phenomenon [45] to a more athero-
genic or proinflammatory composition of the Con-
trol diet. Interestingly, IL-1 Ra was associated with
the intake of saturated fats (increasing effect) and
that of magnesium (decreasing effect), possibly
reflecting high intakes of whole-grain products,
berries and fruits. Magnesium deficiency may also
be directly related to the formation of inflammatory
cytokines [46], and in some cohort studies, magne-
sium intake was inversely associated with systemic
inflammation and endothelial dysfunction [47]. In
the absence of changed CRP and cytokine levels,
decreases in IL-1 Ra and liver fat content were
recently observed after a diet rich in polyunsatu-
rated compared with saturated fatty acids [48].
Furthermore, elevated levels of IL-1 Ra in serum
have been related to nonalcoholic steatohepatitis
[49]. These earlier findings together with our obser-
vations suggest that IL-1 Ra is an interesting and
also highly sensitive inflammation marker respon-
sive to dietary changes. All other inflammatory
markers, including hs-CRP and IL-6, remained
unchanged in the present study. This is in contrast
to our previous observations where we found
reduction in hs-CRP and E-selectin, a marker of
endothelial function, during a diet consisting of
fatty fish, rye bread and bilberries, thus resembling
the present diet [29]. The observed difference
between these two studies could be explained by
the fact that the amounts of rye bread, fatty fish and
bilberries consumed by the study individuals were
higher in our previous study, whereas no major
changes were otherwise allowed, for example, in the
fatty acid composition of the experimental diets[29].
In the present study, according to the study design,
there was an increase in the intake of saturated fat
in the Control diet group, whereas the intake of
saturated fat was reduced in the Healthy diet
group.
Strengths and weaknesses
Despite compliance can be considered satisfactory
when judging self-reported food records, in this
study, the multicentre design including variation
in genetic, cultural and dietary aspects could have
lowered the chances to observe more pronounced
beneficial effects. The larger number of dropouts in
the Control diet group could be criticized, but it is
explained by the fact that the female study partic-
ipants were generally aware of healthy dietary
principles. Therefore, a number of women random-
ized into the Control diet group were not willing to
continue on the control diet. It can be argued that
the variable duration of the study may weaken this
study, but this may not be the case as demon-
strated in the Fig. 3. One of the strengths of this
study is the isocaloric study design achieved for up
to 6 months, which made it possible to examine the
effects of the dietary composition as such on the
outcome measurements of interest without con-
comitant weight changes taking place in many
comparative studies. It should also be noticed that
the way we performed statistical analyses (i.e.
without any exclusions and adjustments) did not
change our conclusions.
From a public health point of view, these results
are encouraging, as even small reductions in non-
HDL-C and LDL-C are considered to have major
impact on CVD morbidity and mortality [1, 3, 7].
Based on the recent data, non-HDL-C predicts even
better the future risk of coronary heart disease
than apo B or LDL-C, and the change in non-HDL-
C in the present study can be estimated to result in
10% reduction in the coronary heart disease risk
[50, 51]. Furthermore, a healthy Nordic dietary
pattern may have other health benefit as suggested
in a recent cohort study in this field [22].
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In summary, this study suggests that it is possible to
establish a healthy Nordic diet based on the Nordic
dietary recommendations and using Nordic and
local food items. Although no effect on insulin
sensitivity and glucose metabolism was detected,
possibly due to the weight-stable conditions, this
diet corrected non-HDL-C and LDL-C to HDL-C and
corresponding apolipoprotein ratios. A counteract-
ing effect on the inflammationmarker IL-1 Ra by the
healthy Nordic diet vs. Control diet is an interesting
new finding.
Conflict of interest statement
None conflicts of interest to declare.
Acknowledgements
Trial registration Clinical Trials.gov.identifier:
NCT00992641. Systems biology in controlled die-
tary interventions and cohort studies (SYSDIET) is
one of the three projects in the Nordic Centre of
Excellence Programme on Food, Nutrition and
Health nominated and funded by NordForsk for
years 2007–2012 (SYSDIET; 070014). This inter-
vention study was also funded by the Academy of
Finland, Finnish Diabetes Research Foundation,
Finnish Foundation for Cardiovascular Research,
The Sigfrid Juselius Foundation, and EVO funding
from Kuopio University Hospital (Finland); the
Druvan Foundation, ESPEN, Skane County Council
Research and Development Foundationl, The
Heart-Lung Foundation, Diabetesfonden and
Foundation Cerealia (Sweden); The Danish Obesity
Research Centre (DanORC, www.danorc.dk), The
Danish Council for Strategic Research (Dairy-
Health, BioFunCarb) (Denmark), The Agricultural
Productivity Fund, The Research Fund of the
University of Iceland (Iceland). The following com-
panies provided food products for the study par-
ticipants: Kesko Food Ltd, Raisio Group (Finland);
Belico Food AB, Fazer Bageri Sverige, Lantm€annen,
Oatly AB, Olle Svensson AB, Procordia Food AB,
Pagen AB, Unilever, Wasabr€od AB (Sweden);
Lantm€annen Food R&D, Jan Import A/S, Ardo A/
S, Scandic Food A/S, WASA, Glyngøre Limfjord A/
S, Royal Greenland A/S, Arla Foods (Denmark);
The Mother Earth Farm at Vallanes (Iceland); and
Unilever Nordic (Sweden, Denmark, Iceland). We
would like to express our thanks to the following
persons for dietary counselling, practical contribu-
tion to this project or technical assistance: Brudy
Zhao Han (building and management of the data-
base for SYSDIET), Maria Lankinen (finalizing the
database), Vanessa de Mello Laaksonen (calculat-
ing insulin sensitivity and secretion indices) Tiina
Lappalainen, Anne J€a€askel€ainen, Kaija Kettunen,
Tuomas Onnukka, Hanne Lysdal Petersen, Britta
Naimi Krath, Sarah Ben Soltane, Asta Hietala,
Marketta Niiranen, Anneli Kangas-Kerkel€a, Eeva
Nissinen, Marja-Leena Kyt€okangas, Saara Korho-
nen and Sari Pyrh€onen (Finland); Margit Bergs-
tr€om, Bertil Nilsson, Hannah Helgegren, Linda
Jonsson and Matilda Ulmius (Skane University
Hospital and Lund University), Ola Kally Magnus-
dottir, Kristjan Thor Gunnarsson, Brynja Bodvars-
dottir (Iceland), Siv Tengblad (for conducting the
fatty acid analyses, Uppsala University, Sweden).
The authors’ responsibilities were as follows: MU,
KH, MJS, IT, KSP, UR and BA had the main
responsibility of the conduction of the study in
each trial centre. US, MK, LB, LC, AJ-P, IG and SEJ
planned the study diets and trained the study
personnel. MO had the responsibility of building
and management of the database. JP had the
responsibility of statistical analyses and made
suggestions on data presentation. KJP analysed
and interpreted the data on inflammatory factors,
and MS and LOD took the main responsibility of
the management of laboratory analyses. MU with
KH, US, IT and UR wrote the first version of the
manuscript. All of the authors belong to the SYS-
DIET consortium, and they substantially contrib-
uted to the study design, conducting the study
(MU, KH, MJS, US, MK, LB, LSM, LC, LOD, TB, AJ-
P, G €O, ML-O, K-HH, JH, FR, DI, IG, SEJ, IT, KSP,
UR, BA), interpreting the data and finalizing the
manuscript. MU has the main responsibility of the
final content.
References
1 Mozaffarian D, Appel LJ, Van Horn L. Components of a
cardioprotective diet: new insights. Circulation 2011; 123:
2870–91.
2 Alberti KGMM, Eckel RH, Grundy SM et al. Harmonizing the
metabolic syndrome: a joint interim statement of the inter-
national diabetes federation task force on epidemiology and
prevention; National Heart, Lung and, Blood Institute; Amer-
ican Heart Association; World Heart Federation; International
Atherosclerosis Society; and International Association for the
Study of Obesity. Circulation 2009; 120: 1640–5.
3 Mozaffarian D, Micha R, Wallace S. Effects on coronary heart
disease of increasing polyunsaturated fat in place of satu-
rated fat: a systematic review and meta-analysis of random-
ized controlled trials. PLoS Med 2010; 7: e1000252.
4 Katan MB, Zock P, Mensink RP. Effects of fats and fatty acids
on blood lipids in humans: an overview. Am J Clin Nutr 1994;
60(Suppl): 1017S–22S.
M. Uusitupa et al. Healthy Nordic diet and CVD risk
64 ª 2013 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine, 2013, 274; 52–66
5 Sniderman A, Couture P, de Graaf J. Diagnosis and treatment
of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol
2010; 6: 335–46.
6 Contois JH, McConnell JP, Sethi AA et al. Apolipoprotein B
and cardiovascular risk: position statement from the AACC
Lipoproteins and Vascular Diseases Division Working Group
Best Practices. Clin Chem 2009; 55: 407–19.
7 Ramjee V, Sperling LS, Jacobson TA. Non-high density lipopro-
tein cholesterol versus apolipoprotein B in cardiovascular risk
stratification.Do theMath.JAmCollCardiol2011;58:457–63.
8 Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol
efflux capacity, high density lipoprotein function, and ath-
erosclerosis. N Engl J Med 2011; 364: 127–35.
9 Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory
disease. Nat Rev Immunol 2011; 11: 98–107.
10 Hansson GK, Hermansson A. The immune system in athero-
sclerosis. Nat Immunol 2011; 12: 204–12.
11 Lopez-Garcia E, Schulze MB, Fung TT et al. Major dietary
patterns are related to plasma concentrations of markers of
inflammation and endothelial dysfunction. Am J Clin Nutr
2004; 80: 1029–35.
12 Basu A. Devaraj Sr, Jialal I. Dietary factors that promote or
retard inflammation. Arterioscler Thromb Vasc Biol 2006; 26:
995–1001.
13 Esposito K, Marfella R, Ciotola M et al. Effect of a Mediterra-
nean–style diet on endothelial dysfunction and markers of
vascular inflammation in the metabolic syndrome. A ran-
domized trial. JAMA 2004; 292: 1440–6.
14 Salas-Salvado J, Garcia-Arellano A, Estruch R et al. PRDI-
MET Investigators. Components of the Mediterranean-type
food pattern and serum inflammatory markers among
patients at high risk for cardiovascular disease. Eur J Clin
Nutr 2008; 62: 651–9.
15 Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to
Mediterranean diet and health status; meta-analysis. BMJ
2008; 337: a1344.
16 Fung TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC,
Hu FB. Mediterranean diet and incidence of and mortality
from coronary heart disease and stroke in women. Circulation
2009; 119: 1093–100.
17 Salas-Salvado J, Bullo M, Babio N et al. PREDIMED Study
Investigators. Reduction in the incidence of type 2 diabetes
with the Mediterranean diet: results of the PREDIMED-Reus
nutrition intervention randomized trial. Diabetes Care 2011;
34: 14–9.
18 Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi
A. Mediterranean diet pyramid: a cultural model for healthy
eating. Am J Clin Nutr 1995; 61: S1402–19.
19 Papadaki A, Scott JA. The impact on eating habits of
temporary translocation from a Mediterranean to a Northern
European environment. Eur J Clin Nutr 2002; 56: 455–61.
20 Roininen K, Tuorila H, Zandstra EH et al. Differences in
health and taste attitudes and reported behavior among
Finnish, Dutch and British consumers: a cross-national
validation of the Health and Taste Attitude Scales [HTAS].
Appetite 2001; 37: 33–45.
21 Bere E, Brug J. Towards health-promoting and environmen-
tally friendly regional diets - a Nordic example. Public Health
Nutr 2009; 12: 91–6.
22 Olsen A, Egeberg R, Halkjaer J, Christensen J, Overvad K,
Tjonneland A. Healthy aspects of the Nordic diet are related to
lower total mortality. J Nutr 2011; 141: 639–44.
23 Adamsson V, Reumark A, Fredriksson I-B et al. Effects of a
healthy Nordic diet on cardiovascular risk factors in hyper-
cholesterolemic subjects: a randomized controlled trial [NOR-
DIET]. J Intern Med 2011; 269: 150–9.
24 Jenkins DJ, Kendall CW, McKeown-Eyessen G et al.
Effect of a low-glycemic index or a high-cereal fiber diet
on type 2 diabetes: a randomized trial. JAMA 2008; 300:
2742–53.
25 Spitzer RL, Yanovski S, Wadden T, Wing R, Marcus MD. Binge
eating disorder: its further validation in a multisite study. Int
J Eat Disord 1993; 13: 137–53.
26 Nordic Nutrition Recommendations. 4th Edition Intergrading
Nutrition and Physical activityNord 2004:13. Copenhagen:
Nordic Council of Ministers, 2004.
27 Boberg M, Croon LB, Gustafsson I-B, Vessby B. Platelet fatty
acid composition in relation to fatty acid composition in
plasma and to serum lipoprotein lipids in healthy subjects
with special reference to the linoleic acid pathway. Clin Sci
1985; 68: 581–7.
28 Stancakova A, Javorsky M, Kuulasmaa T, Haffner SM,
Kuusisto J, Laakso M. Changes in insulin sensitivity and
release in relation to glycemia and glucose tolerance in 6,414
Finnish men. Diabetes 2009; 58: 1212–21.
29 de Mello VD, Schwab U, Kolehmainen M et al. A diet high in
fatty fish, bilberries and wholegrain products improves
markers of endothelial function and inflammation in individ-
uals with impaired glucose metabolism in a randomised
controlled trial: the Sysdimet study. Diabetologia 2011; 54:
2755–67.
30 Pinheiro J, Bates D, DebRoy S, Sarkar D; the R Development
Core Team. nlme: Linear and Nonlinear Mixed Effects Models.
R package version 3.1-102. Available at: http://cran.
r-project.org/web/packages/nlme/ [accessed March 2012].
31 R Development Core Team. R: A Language and Environment
for Statistical Computing. Vienna, Austria: R Foundation for
Statistical Computing, 2011. ISBN 3-900051-07-0, URL
http://www.R-project.org/. Accessed March 30 2012.
32 Bonaa K. Epidemiological and intervention studies on the
effect of marine polyunsaturated fatty acids on blood
pressure. J Intern Med 1989; 225(Suppl 1): 105–10.
33 Iggman D, Gustafsson I-B, Berglund L, Vessby B, Marck-
mann P, Riserus U. Replacing dairy fat with rapeseed oil
causes rapid improvement of hyperlipidaemia: a randomized
controlled study. J Intern Med 2011; 270: 356–64.
34 Obarzanek E, Sacks FM, Vollmer WM et al. DASH Research
group. Effects on blood lipids of a blood pressure-lowering
diet: the Dietary Approaches to Stop Hypertension [DASH]
Trial. Am J Clin Nutr 2001; 74: 80–9.
35 Basu A, Rhone M, Lyons TJ. Berries: emerging impact on
cardiovascular health. Nutr Rev 2010; 68: 168–77.
36 Erlund I, Koli R, Alfthan G et al. Favorable effects of berry
consumption on platelet function, blood pressure, and HDL
cholesterol. Am J Clin Nutr 2008; 87: 323–31.
37 Frost G, Leeds AA, Dore CJ, Madeiros S, Brading S, Dorn-
horst A. Glycaemic index as a determinant of serum HDL-
cholesterol concentration. Lancet 1999; 353: 1045–8.
38 Michalsen A, Lehmann N, Pithan C et al. Mediterranean diet
has no effect on markers of inflammation and metabolic risk
factors in patients with coronary heart disease. Eur J Clin Nutr
2006; 60: 478–85.
39 Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of
the effects of dietary patterns on blood pressure. DASH
M. Uusitupa et al. Healthy Nordic diet and CVD risk
ª 2013 The Association for the Publication of the Journal of Internal Medicine 65
Journal of Internal Medicine, 2013, 274; 52–66
Collaborative Research Group. N Engl J Med 1997; 336:
1117–24.
40 Festa A, Hanley AJ, Tracy RP, D’Agostino R Jr, Haffner SM.
Inflammation in the prediabetic state is related to increased
insulin resistance rather than decreased insulin secretion.
Circulation 2003; 108: 1822–30.
41 Salmenniemi U, Ruotsalainen E, Pihlajam€aki J et al.Multiple
abnormalities in glucose tolerance and energy metabolism
and coordinated changes in levels of adiponectin, cytokines,
and adhesion molecules in subjects with metabolic syn-
drome. Circulation 2004; 110: 3842–8.
42 Carstensen M, Herder C, Kivim€aki M et al. Accelerated
increase in serum interleukin-1 receptor antagonist starts
6 years before diagnosis of type 2 diabetes: Whitehall II
prospective cohort study. Diabetes 2010; 59: 1222–7.
43 Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabak
A. Elevated levels of anti-inflammatory interleukin-1 receptor
antagonist precede the onset of type 2 diabetes. Diabetes Care
2009; 32: 421–3.
44 Luotola K, Pietil€a A, Zeller T et al. Associations between
interleukin- [IL-1] gene variations or IL-receptor antagonist
levels and the development of type 2 diabetes. J Intern Med
2010; 269: 322–32.
45 Hurme M, Santtila S. IL-1 receptor antagonist [IL-1Ra]
plasma levels are co-ordinately regulated by both IL-Ra and
IL-1 beta genes. Eur J Immunol 1998; 28: 2598–602.
46 Weglicki WB, Phillips TM. Pathobiology of magnesium defi-
ciency: a cytokine/neurogenic inflammation hypothesis. Am
J Physiol 1992; 263(3 Pt 2): R734–7.
47 Song Y, Li TY, van Dam RM, Manson JE, Hu FB. Magnesium
intake and plasma concentrations of markers of systemic
inflammation and endothelial dysfunction in women. Am
J Clin Nutr 2007; 85: 1068–74.
48 Bjermo H, Iggman D, Kullberg J et al. Effect of n-6 polyun-
saturated versus saturated fat on liver fat, lipoprotein
metabolism and inflammation in abdominal obesity. A ran-
domized controlled trial. Am J Clin Nutr 2012; 95: 1003–12.
49 Pihlajam€aki J, Kuulasmaa T, Kaminska D et al. Serum
interleukin 1 receptor antagonist as an independent marker
of non-alcoholic steatohepatitis in humans. J Hepatol 2012;
56: 663–70.
50 Boekholdt SM, Arsenault BJ, Mora S et al. Association of
LDL-cholesterol, non-HDL-cholesterol and apolipoprotein B
levels with the risk of cardiovascular events among patients
treated with statins. JAMA 2012; 307: 1302–9.
51 Robinson JG, Wang S, Jacobson TA. Meta-analysis of
comparison of effectiveness og lowering apolipoprotein B
versus low-density lipoprotein cholesterol and nonhigh-
density lipoprotein cholesterol for cardiovascular risk
reduction in randomized trials. Am J Cardiol 2012; 110:
1468–76.
Correspondence: Matti Uusitupa, University of Eastern Finland,
Kuopio campus, PO Box 1627 70211 Kuopio, Finland.
(fax: +358-17-162792; e-mail: matti.uusitupa@uef.fi).
Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Table S1. Goals of nutrient composition of the
study diets.
Table S2. Serum phospholipid fatty acid composi-
tion (as percentage) at baseline and at the end of
the study (mean and SD) by group and the group
difference at the end of the study with 95% CI.
M. Uusitupa et al. Healthy Nordic diet and CVD risk
66 ª 2013 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine, 2013, 274; 52–66
